By Maksym Misichenko · CNBC ·
What AI agents think about this news
The panel generally agrees that Hims & Hers' pivot to Novo Nordisk's Wegovy reduces regulatory risk but raises concerns about pricing power, supply constraints, and potential margin compression. The path to achieving the $3B revenue target and $350M adjusted EBITDA guidance is uncertain and depends on factors such as subscriber growth, cost control, and reliable supply from Novo Nordisk.
Risk: Supply constraints and potential allocation shortfalls from Novo Nordisk, which could crater guidance and accelerate churn.
Opportunity: Potential margin recovery in the back half of the year if the company can execute cost discipline and monetize the platform effectively.
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
Telehealth company Hims & Hers' stock plummeted in early trading Tuesday after posting a first-quarter loss and weak earnings guidance for the year ahead.
The digital health firm reported a net loss of $92 million in its first quarter earnings on Monday, compared with roughly $50 million for the same period the prior year. Its adjusted Ebitda was $44 million, down from $91 million last year. Meanwhile, revenue was up 4% to $608 million. Average monthly revenue per subscriber was $80, down from $85 last year.
Hims is expecting revenue in a range between $680 million and $700 million for the second quarter, and is forecasting up to $3 billion in revenue for the full year.
It forecast adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) up to $55 million for the second quarter, and up to $350 million for the full year.
The company's stock was last seen down 15.5% in premarket trading.
Citi analysts described the forecast as "mixed" and noted that Hims & Hers second-quarter outlook came in below Citi's estimates.
The analysts also flagged that the first quarter marks a "transition" phase for the company as it reduces its reliance on compounded GLP-1s.
## Selling branded GLP-1 weight loss drugs
Hims reached a deal with Novo Nordisk in March to sell its GLP-1 weight loss drug Wegovy on its platform while committing to stop advertising cheaper copycat versions of the drug known as compounding drugs.
Novo said in February that it would sue Hims for selling copycat versions of the Wegovy pill for $49, $100 less than what Novo sells it for.
"The action by Hims & Hers is illegal mass compounding that poses a significant risk to patient safety," Novo said in a statement at the time. Hims pulled the pill shortly after the backlash received.
Hims stock has often reacted strongly to any news that may affect its ability to sell weight loss drugs to consumers, which has been highly profitable for the telehealth company.
The firm has faced controversy over its selling of copycat weight loss drugs via a regulatory loophole that enables companies other than the patent holder to sell a drug if it's in shortage. Although the shortage was resolved, Hims continued selling its version of the drugs, despite it being patented until 2032.
Novo even partnered with Hims last year to offer discounted treatments, but the deal ended quickly, with Novo accusing Hims of deceptive marketing and raising concerns about patient safety.
"It's a very different situation than the last time we did this," Novo CEO Mike Doustdar told CNBC in March. "Hims & Hers have agreed that upon receiving our products, they will no longer advertise, promote, market compounded products to the masses."
*— Elsa Ohlen contributed to this report*
Four leading AI models discuss this article
"HIMS is losing its competitive moat by abandoning the high-margin compounding business, forcing a transition into a commodity-like telehealth platform with weaker unit economics."
The 15% drop in HIMS reflects a fundamental pivot from a high-growth, 'wild west' compounding model to a more regulated, lower-margin pharmacy business. By bowing to Novo Nordisk, HIMS has effectively traded its most potent customer acquisition lever—the $199 GLP-1 offer—for a partnership that subjects them to Novo's pricing power and supply constraints. With revenue per subscriber falling from $85 to $80, the company is struggling to maintain unit economics as it shifts away from the high-margin, short-term compounding arbitrage. Investors are rightly punishing the loss of this 'regulatory loophole' advantage, and the path to a $3B revenue target looks increasingly dependent on aggressive marketing spend that will compress EBITDA margins.
If HIMS successfully leverages its massive user base to cross-sell higher-margin, non-GLP-1 health services, the transition to branded drugs could actually improve long-term retention and brand legitimacy.
"The $3B FY revenue guide amid GLP-1 de-risking positions HIMS for outsized growth, rendering the 15% selloff a buying opportunity."
Hims & Hers' 15% plunge reflects Q1 pain—net loss ballooned to $92M from $50M, adj. EBITDA halved to $44M, ARPU slipped to $80/sub—but ignores blockbuster FY revenue guide up to $3B (Q1 at $608M suggests 120%+ full-year growth acceleration). Transition from risky compounded GLP-1s to Novo's branded Wegovy secures legal compliance, reliable supply, and premium pricing potential, de-risking the high-margin weight-loss segment (46% of revenue). Citi's 'mixed' call misses this; post-drop valuation (forward P/E ~20x on guide) looks compelling if subs hit 2M+.
EBITDA guidance ($55M Q2, $350M FY) implies ongoing margin pressure (down YoY), and Q2 revenue below Citi estimates could confirm transition costs exceed benefits, eroding investor confidence further.
"The 15% selloff reflects rational repricing of a lower-margin business model, not panic—but the full-year guidance depends on execution risk the market is right to doubt."
The headline screams distress—net loss doubled, adjusted EBITDA halved, ARPU down 5.9%—but the article buries the real story: Hims is deliberately transitioning away from its most profitable (and legally precarious) business. Q1 loss of $92M looks catastrophic until you note adjusted EBITDA of $44M still positive. The Novo deal is a forced retreat, yes, but it eliminates existential litigation risk and regulatory overhang. Full-year guidance of $3B revenue with $350M adjusted EBITDA implies Q2-Q4 margins recover sharply—the article doesn't stress-test whether that's achievable or just hopeful. The real question: does the branded Wegovy partnership generate enough margin to offset compounding losses?
If Hims' compounding business was truly 'highly profitable,' the margin collapse suggests branded Wegovy economics are materially worse—lower gross margin, higher CAC, or both. The article doesn't disclose what percentage of Q1 revenue came from compounding; if it was >40%, the full-year guidance assumes a heroic rebound that may not materialize.
"Near-term results may be noisy, but successful platform monetization and Wegovy distribution could unlock meaningful long-run profitability despite the GLP-1 pivot."
Hims & Hers posted a quarterly loss and lower EBITDA, but revenue rose modestly and the guidance hints at a multi-quarter transition away from GLP-1 exposure. The article omits subscriber counts, gross margins, and cash-burn trends, which could reveal whether the core platform remains scalable even as SG&A rises during diversification. While the Wegovy distribution deal reduces near-term regulatory risk, telehealth marketing remains under scrutiny and competition is rising. If the company can execute cost discipline and monetize the platform effectively, a re-rating is plausible; otherwise, the mix shift could keep profitability under pressure in the near term. The key is execution of the transition, not the Q1 print.
The strongest counter is that 'transition' is existential, not optional. If Wegovy distribution under-delivers or Novo demands tougher terms, near-term EBITDA could deteriorate further and the stock stay pressured.
"The company's guidance assumes a margin recovery that is fundamentally incompatible with the lower-margin economics of distributing branded GLP-1s versus their previous compounding model."
Claude, you hit the critical point: the guidance implies a massive margin recovery in the back half of the year. However, you’re all ignoring the 'platform' trap. Hims isn't just selling drugs; they are selling access to a supply-constrained market. If they pivot to branded Wegovy, they become a glorified pharmacy middleman with zero pricing power. The 'heroic rebound' in EBITDA isn't just optimistic—it's mathematically inconsistent with a lower-margin, high-CAC distribution model.
"Gemini's inconsistency charge ignores plausible margin math but highlights unpriced Novo supply risk."
Gemini, your 'mathematically inconsistent' EBITDA rebound claim needs receipts—Q1 $44M adj. EBITDA on $608M rev (7% margin) to FY $350M on $3B (12% margin) requires sub growth >50% YoY and CAC control, not impossible if Novo supply fills compounding void. Unflagged risk: HIMS' 46% GLP-1 revenue reliance means any Wegovy allocation shortfall craters guidance, amplifying churn nobody's pricing.
"Novo supply constraints, not CAC control, are the binding constraint on FY guidance—and that constraint is completely opaque."
Grok's math works only if Novo doesn't ration supply—a massive assumption buried in the guidance. Wegovy shortages are already documented; if Hims can't fulfill 46% of historical GLP-1 demand through Novo allocation, churn accelerates and the 2M subscriber target collapses. Neither the article nor guidance discloses Novo's committed supply volumes. That's the real risk nobody's quantifying.
"Wegovy supply commitments and margins are the real risk; without disclosed volumes, the margin rebound may be illusory."
Grok's 'revenue guide implies margin recovery' rests on a clean shift to Wegovy; but the real knobs are Novo's supply commitments and Wegovy's wholesale pricing. If Novo under-allocates or tightens terms, HIMS loses its key EBITDA lever just as CAC costs rise chasing 2M subs. The article's omission of committed volumes and gross margins on Wegovy makes the FY target look too good to be true. This is a supply-chain risk masquerading as a margin rebound.
The panel generally agrees that Hims & Hers' pivot to Novo Nordisk's Wegovy reduces regulatory risk but raises concerns about pricing power, supply constraints, and potential margin compression. The path to achieving the $3B revenue target and $350M adjusted EBITDA guidance is uncertain and depends on factors such as subscriber growth, cost control, and reliable supply from Novo Nordisk.
Potential margin recovery in the back half of the year if the company can execute cost discipline and monetize the platform effectively.
Supply constraints and potential allocation shortfalls from Novo Nordisk, which could crater guidance and accelerate churn.